Oral vaccination of piglets against Mycoplasma hyopneumoniae using silica SBA-15 as an adjuvant effectively reduced consolidation lung lesions at slaughter.
Adjuvants, Immunologic
Administration, Oral
Animals
Bacterial Vaccines
/ administration & dosage
Biopsy
Bronchoalveolar Lavage Fluid
/ immunology
Cytokines
/ metabolism
Immunoglobulin A
/ immunology
Immunoglobulin G
/ immunology
Immunohistochemistry
Lung
/ immunology
Mycoplasma hyopneumoniae
/ classification
Pneumonia of Swine, Mycoplasmal
/ microbiology
Real-Time Polymerase Chain Reaction
Silicon Dioxide
Swine
Treatment Outcome
Vaccination
/ methods
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 11 2021
17 11 2021
Historique:
received:
05
05
2021
accepted:
02
11
2021
entrez:
18
11
2021
pubmed:
19
11
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Mycoplasma (M.) hyopneumoniae is the main pathogen of porcine enzootic pneumonia (PEP). Its controlling is challenging, and requires alternative strategies. This study aimed to develop an oral vaccine against M. hyopneumoniae using a nanostructured mesoporous silica (SBA-15) as an adjuvant, and compare its effect with an intramuscular (IM) commercial vaccine (CV). Fifty 24 day-old M. hyopneumoniae-free piglets composed five equal groups for different immunization protocols, consisting of a CV and/or oral immunization (OI). Control piglets did not receive any form of immunization. All piglets were challenged with M. hyopneumoniae strain 232 on D49 by tracheal route. IgA antibody response in the respiratory tract, bacterial shedding and serum IgG were evaluated. The piglets were euthanized on 28 (D77) and 56 (D105) days post-infection. Lung lesions were macroscopically evaluated; lung fragments and bronchoalveolar fluid (BALF) were collected for estimation of bacterial loads by qPCR and/or histopathology examination. All immunization protocols induced reduction on Mycoplasma-like macroscopic lung lesions. IgA Ab responses anti-M. hyopneumoniae, the expression of IL-4 cytokine and a lower expression of IL-8 were induced by CV and OI vaccines, while IgG was induced only by CV. Oral immunization using silica as a carrier-adjuvant can be viable in controlling M. hyopneumoniae infection.
Identifiants
pubmed: 34789792
doi: 10.1038/s41598-021-01883-2
pii: 10.1038/s41598-021-01883-2
pmc: PMC8599662
doi:
Substances chimiques
Adjuvants, Immunologic
0
Bacterial Vaccines
0
Cytokines
0
Immunoglobulin A
0
Immunoglobulin G
0
SBA-15
0
Silicon Dioxide
7631-86-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
22377Subventions
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : #2019/19710-4
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo
ID : #2018/12742-5
Informations de copyright
© 2021. The Author(s).
Références
Vet Immunol Immunopathol. 2014 Oct 15;161(3-4):211-21
pubmed: 25194591
Small. 2006 Feb;2(2):254-6
pubmed: 17193031
Vet Rec. 2002 Nov 2;151(18):535-8
pubmed: 12448490
Vet J. 2011 Apr;188(1):48-52
pubmed: 20605734
Mol Immunol. 2015 Jul;66(1):22-34
pubmed: 25242212
Vet Microbiol. 2007 May 16;122(1-2):97-107
pubmed: 17303351
BMC Vet Res. 2012 Jan 06;8:2
pubmed: 22225838
Vaccine. 2006 Nov 30;24(49-50):7081-6
pubmed: 16934376
Immunol Cell Biol. 2004 Oct;82(5):488-96
pubmed: 15479434
Prev Vet Med. 2000 Jun 12;45(3-4):221-35
pubmed: 10821962
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
J Bacteriol. 2004 Nov;186(21):7123-33
pubmed: 15489423
Annu Rev Immunol. 1993;11:165-90
pubmed: 8386517
Vet Microbiol. 2004 Jun 3;100(3-4):255-68
pubmed: 15145504
Vet Microbiol. 2013 Dec 27;167(3-4):417-24
pubmed: 24035264
Nanomedicine. 2016 Nov;12(8):2241-2250
pubmed: 27339784
Vaccine. 2019 Oct 8;37(43):6415-6425
pubmed: 31519445
Aust Vet J. 1997 Jul;75(7):504-11
pubmed: 9258425
Vet Immunol Immunopathol. 2004 Dec 8;102(3):329-38
pubmed: 15507316
Sci Rep. 2019 Apr 15;9(1):6106
pubmed: 30988384
BMC Vet Res. 2017 Sep 15;13(1):285
pubmed: 28915878
Vaccine. 2009 Mar 13;27(12):1875-9
pubmed: 19114074
Res Vet Sci. 2011 Dec;91(3):e68-72
pubmed: 21147491
Vaccine. 2009 Jul 16;27(33):4543-50
pubmed: 19433128
Nucleic Acids Res. 2012 Aug;40(15):e115
pubmed: 22730293
Vet Microbiol. 2020 May;244:108647
pubmed: 32402328
Vet Microbiol. 2018 Sep;223:86-92
pubmed: 30173757
Nanomedicine (Lond). 2018 Aug 1;13(15):1939-1962
pubmed: 30152253
Vet Immunol Immunopathol. 2014 Jun 15;159(3-4):202-7
pubmed: 24630952
Einstein (Sao Paulo). 2015 Jul-Sep;13(3):469-73
pubmed: 26466066
J Comp Pathol. 2016 Feb-Apr;154(2-3):125-34
pubmed: 26774274
Vet Microbiol. 2012 May 4;156(3-4):315-21
pubmed: 22138620
J Clin Microbiol. 2003 Sep;41(9):4172-7
pubmed: 12958243
J Leukoc Biol. 2004 Feb;75(2):163-89
pubmed: 14525967
Genet Mol Res. 2014 Jul 07;13(3):5199-206
pubmed: 25061745
Allergy Asthma Immunol Res. 2017 Mar;9(2):107-115
pubmed: 28102055
Vet Microbiol. 1994 Apr;39(3-4):261-73
pubmed: 8042274
J Appl Microbiol. 2018 Aug;125(2):345-355
pubmed: 29603531
Regul Toxicol Pharmacol. 2020 Apr;112:104618
pubmed: 32087352
Front Immunol. 2019 May 24;10:1087
pubmed: 31178860
Vet Microbiol. 2001 Feb 26;78(4):331-41
pubmed: 11182499
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Vaccine. 2004 Jun 2;22(17-18):2328-33
pubmed: 15149792
Am J Vet Res. 2000 Nov;61(11):1384-9
pubmed: 11108184
Vaccine. 2010 Nov 23;28(50):7829-36
pubmed: 20937318
Vet Microbiol. 2014 Jan 31;168(2-4):357-64
pubmed: 24332702
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
J Vet Med Sci. 2003 Jan;65(1):69-74
pubmed: 12576707
PLoS One. 2017 Apr 5;12(4):e0175034
pubmed: 28380065
Vet Microbiol. 2000 Oct 1;76(3):299-303
pubmed: 10973704